Mingzhu Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mingzhu Li has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Lihui Wei
Department of Obstetrics and Gynecology, Peking University People’s Hospital, Beijing 100044, China
10 shared publications - Chao Zhao
Department of Obstetrics and Gynecology, Peking University People’s Hospital, No. 11 Xizhimen South Street, Beijing 100044, China
3 shared publications Jingran Li
3 shared publications- Jingran Li
Department of Obstetrics and Gynecology, Peking University People’s Hospital, No. 11 Xizhimen South Street, Beijing 100044, China
3 shared publications - Long Sui
Department of Gynecology and Obstetrics, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
3 shared publications Qing Cong
3 shared publications
Latest Publications
- Open Access
Is Endocervical Curettage (ECC) Necessary for All HPV16/18-Positive Patients? A Stratified Analysis of 670 Cases
Background: High-risk HPV16/18 subtypes account for over 70% of cervical cancers, but should all HPV16/18-positive patients routinely undergo endocervical curettage (ECC)? Methods: A retrospective cohort study was conducted on 670 HPV16/18-positive patients who underwent colposcopy at Peking University People’s Hospital from 2021 to 2024. Stratified analysis was performed based on prior HPV infection history, current cervical cytology and HPV test results, transformation zone (TZ) type, and colposcopic impression. Primary outcome was the detection rate of cervical intraepithelial neoplasia above (CIN2)+ on final pathology and the additional diagnostic yield of ECC in the ECC subgroup. Results: Among the 670 HPV16/18-positive women, CIN2+ was identified in 32.5% (218/670); the CIN2+ group was significantly younger than the < CIN2 group (median 36.5 vs. 41.0 years, p < 0.001). A high-grade colposcopic impression (G2) steeply elevated the observed CIN2+ proportion to 100%, especially combined with high-grade cytology. In contrast, a Normal/G1 colposcopic finding effectively downgraded the risk to 4.8% in the presence of prior HPV negativity + low-grade cytology + visible TZ. Among the 523 ECC specimens, it is noteworthy that even when the final pathology was diagnosed as CIN2+, a considerably high proportion of patients (44.4–64.7%) remained free of lesions in the endocervical canal; in the colposcopy impression (G2) population, 68.1% of the ECC was normal. The incremental yield of ECC over directed biopsy was only 2.7% (14/523), and all 14 incremental cases occurred in TZ3 (100%). Among the 146 women meeting the composite low-risk profile (TZ1/2 combined with a Normal/G1 colposcopic impression), none had an incremental CIN2+ detection. Conclusion: Women with HPV16/18-positive CIN2+ lesions presented at a younger age. Approximately one-third were diagnosed with CIN2+, and more than half of these had normal ECC histology. With a low additional diagnostic rate observed, ECC provided incremental diagnostic benefit in only 2.7% of HPV16/18-positive women undergoing colposcopy, almost exclusively among patients with a Type 3 transformation zone. The composite low-risk profile identified a subgroup with an extremely low additional diagnostic yield of ECC; however, prospective validation is required before the omission of ECC in this subgroup can be recommended as a change in clinical practice.
Open AccessIs Endocervical Curettage (ECC) Necessary for All HPV16/18-Positive Patients? A Stratified Analysis of 670 Cases
Background: High-risk HPV16/18 subtypes account for over 70% of cervical cancers, but should all HPV16/18-positive patients routinely undergo endocervical curettage (ECC)? Methods: A retrospective cohort study was conducted on 670 HPV16/18-positive patients who underwent colposcopy at Peking University People’s Hospital from 2021 to 2024. Stratified analysis was performed based on prior HPV infection history, current cervical cytology and HPV test results, transformation zone (TZ) type, and colposcopic impression. Primary outcome was the detection rate of cervical intraepithelial neoplasia above (CIN2)+ on final pathology and the additional diagnostic yield of ECC in the ECC subgroup. Results: Among the 670 HPV16/18-positive women, CIN2+ was identified in 32.5% (218/670); the CIN2+ group was significantly younger than the < CIN2 group (median 36.5 vs. 41.0 years, p < 0.001). A high-grade colposcopic impression (G2) steeply elevated the observed CIN2+ proportion to 100%, especially combined with high-grade cytology. In contrast, a Normal/G1 colposcopic finding effectively downgraded the risk to 4.8% in the presence of prior HPV negativity + low-grade cytology + visible TZ. Among the 523 ECC specimens, it is noteworthy that even when the final pathology was diagnosed as CIN2+, a considerably high proportion of patients (44.4–64.7%) remained free of lesions in the endocervical canal; in the colposcopy impression (G2) population, 68.1% of the ECC was normal. The incremental yield of ECC over directed biopsy was only 2.7% (14/523), and all 14 incremental cases occurred in TZ3 (100%). Among the 146 women meeting the composite low-risk profile (TZ1/2 combined with a Normal/G1 colposcopic impression), none had an incremental CIN2+ detection. Conclusion: Women with HPV16/18-positive CIN2+ lesions presented at a younger age. Approximately one-third were diagnosed with CIN2+, and more than half of these had normal ECC histology. With a low additional diagnostic rate observed, ECC provided incremental diagnostic benefit in only 2.7% of HPV16/18-positive women undergoing colposcopy, almost exclusively among patients with a Type 3 transformation zone. The composite low-risk profile identified a subgroup with an extremely low additional diagnostic yield of ECC; however, prospective validation is required before the omission of ECC in this subgroup can be recommended as a change in clinical practice.
- Open Access
- 30 July 2026
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 6 (3) , e000500
Chinese expert consensus on the management of cervical intraepithelial neoplasia grade 2 (CIN 2) (2026 edition)
- 30 July 2026
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 6 (3) , e000500
Open AccessChinese expert consensus on the management of cervical intraepithelial neoplasia grade 2 (CIN 2) (2026 edition)
- Open Access
- 18 September 2025
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 5 (3) , e000285
Guidelines for the clinical application of prophylactic human papillomavirus (HPV) vaccines in China (2025 edition)
Prophylactic human papillomavirus (HPV) vaccination is a primary preventive measure aimed at preventing HPV-related lesions and cancers by preventing HPV infection. With the continuous update of global data on HPV vaccination, seven academic societies—including the Chinese Society for Colposcopy and Cervical Pathology of China Healthy Birth Science Association and Chinese Society of Gynecological oncology, Chinese Medical Association and others—have jointly developed the Guidelines for the Clinical Application of Prophylactic Human Papillomavirus (HPV) Vaccines in China (2025 Edition). This guideline was based on the previous Chinese Expert Consensus on the Clinical Application of Human Papillomavirus Vaccines1 as well as current evidence-based medical research, China’s national conditions and clinical realities. The recommended categories of this guideline are listed in table 1.
- 18 September 2025
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 5 (3) , e000285
Open AccessGuidelines for the clinical application of prophylactic human papillomavirus (HPV) vaccines in China (2025 edition)
Prophylactic human papillomavirus (HPV) vaccination is a primary preventive measure aimed at preventing HPV-related lesions and cancers by preventing HPV infection. With the continuous update of global data on HPV vaccination, seven academic societies—including the Chinese Society for Colposcopy and Cervical Pathology of China Healthy Birth Science Association and Chinese Society of Gynecological oncology, Chinese Medical Association and others—have jointly developed the Guidelines for the Clinical Application of Prophylactic Human Papillomavirus (HPV) Vaccines in China (2025 Edition). This guideline was based on the previous Chinese Expert Consensus on the Clinical Application of Human Papillomavirus Vaccines1 as well as current evidence-based medical research, China’s national conditions and clinical realities. The recommended categories of this guideline are listed in table 1.
- Open Access
- 1 July 2025
- Published by BMJ in BMJ Public Health
- Vol. 3 (2) , e001565
Distribution and extended triage of high-risk human papillomavirus genotyping based on vaginal self-sampling
Background: To investigate the overall and type-specific prevalence of high-risk human papillomavirus (HR-HPV) infection in China across different age groups and regions and to evaluate the triage of HPV-positive cases. Methods: A prospective cross-sectional study recruited a total of 20 103 women aged 30–59 years from 13 provinces in China. Self-collected vaginal samples were tested for 14 HR-HPV types using next-generation sequencing or multiplex real-time PCR assays. Results: The five most common types were HPV52, 58, 16, 39 and 51. The prevalence of single-type HR-HPV was 10.70%. The overall proportion of HPV16/18 was 20.67%, with a significant difference observed among provinces (p<0.05). The age-specific prevalence curve of HR-HPV followed a U-shaped pattern from 30 to 59 years, with a lower prevalence observed in women aged 40–44 years (12.35%), which subsequently changed with age. The proportion of women aged 30–34 years with HPV16 (21.59%) was significantly higher than that in other age groups, showing two peaks in young and older women. There was a significantly higher prevalence of HPV16 single-type infection in the youngest group, whereas HPV16 multi-type infection was higher in older women. Among cervical intraepithelial neoplasia grade 2 or higher (CIN)2+ cases, HPV16 infection accounted for 43.98%, HPV18 infection for 7.84%, and other 12 infections for 48.20%. HPV16 had the highest sensitivity for detecting CIN2+, reaching 42.7% among single HPV types, followed by HPV52 and HPV58. When HPV16/18/33 were combined for detection, the sensitivity for detecting CIN2+ increased to 66.67%. Conclusions: The prevalence and genotype distribution of HR-HPV based on vaginal self-sampling varied across different regions and ages in China. HPV16 was more prevalent in both younger and older age groups. Different HPV subtypes have different detection rates for CIN2+, and combining HPV16/18/33 significantly improved the sensitivity for detecting CIN2+.
- 1 July 2025
- Published by BMJ in BMJ Public Health
- Vol. 3 (2) , e001565
Open AccessDistribution and extended triage of high-risk human papillomavirus genotyping based on vaginal self-sampling
Background: To investigate the overall and type-specific prevalence of high-risk human papillomavirus (HR-HPV) infection in China across different age groups and regions and to evaluate the triage of HPV-positive cases. Methods: A prospective cross-sectional study recruited a total of 20 103 women aged 30–59 years from 13 provinces in China. Self-collected vaginal samples were tested for 14 HR-HPV types using next-generation sequencing or multiplex real-time PCR assays. Results: The five most common types were HPV52, 58, 16, 39 and 51. The prevalence of single-type HR-HPV was 10.70%. The overall proportion of HPV16/18 was 20.67%, with a significant difference observed among provinces (p<0.05). The age-specific prevalence curve of HR-HPV followed a U-shaped pattern from 30 to 59 years, with a lower prevalence observed in women aged 40–44 years (12.35%), which subsequently changed with age. The proportion of women aged 30–34 years with HPV16 (21.59%) was significantly higher than that in other age groups, showing two peaks in young and older women. There was a significantly higher prevalence of HPV16 single-type infection in the youngest group, whereas HPV16 multi-type infection was higher in older women. Among cervical intraepithelial neoplasia grade 2 or higher (CIN)2+ cases, HPV16 infection accounted for 43.98%, HPV18 infection for 7.84%, and other 12 infections for 48.20%. HPV16 had the highest sensitivity for detecting CIN2+, reaching 42.7% among single HPV types, followed by HPV52 and HPV58. When HPV16/18/33 were combined for detection, the sensitivity for detecting CIN2+ increased to 66.67%. Conclusions: The prevalence and genotype distribution of HR-HPV based on vaginal self-sampling varied across different regions and ages in China. HPV16 was more prevalent in both younger and older age groups. Different HPV subtypes have different detection rates for CIN2+, and combining HPV16/18/33 significantly improved the sensitivity for detecting CIN2+.
- Open Access
- 27 May 2025
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 5 (2) , e000205
Guidelines for cervical cancer screening in China II
Cervical cancer is a common malignant tumour that has become a major global public health issue, seriously threatening women’s lives. In November 2020, the WHO released a global strategy to accelerate the elimination of cervical cancer as a public health problem. So far, the proposal has received positive responses and commitments from 194 countries around the world, including China, which has actively promoted the prevention and treatment of cervical cancer nationwide. In support of the WHO initiative, in January 2023, the Chinese National Health Commission, along with other entities, issued a 7-year Action Plan for Accelerating the Elimination of Cervical Cancer (2023–2030), which primarily focused on improving the cervical cancer prevention and control service system and on strengthening its overall capacity. Furthermore, based on research evidence and practical experience, experts from seven Chinese academic societies—including the Chinese Society for Colposcopy and Cervical Pathology of China Healthy Birth Science Association and Chinese Society of Gynecological Oncology, Chinese Medical Association—have recently published the Guidelines for cervical cancer screening in China II (Guideline II). Unlike the previous Guidelines for cervical cancer screening in China I (Guideline I),1 which primarily focused on primary screening methods for cervical cancer, Guideline II emphasises the management and triage of abnormal primary screening results. As part of tertiary prevention, both screening and triage are critical steps in preventing the progression of cervical cancer, especially for those with abnormal test results. Here, we present a new guideline focused on standardising the triage of abnormal cervical cancer screening to improve management, reduce missed diagnoses and prevent overdiagnosis.
- 27 May 2025
- Published by BMJ in Gynecology and Obstetrics Clinical Medicine
- Vol. 5 (2) , e000205
Open AccessGuidelines for cervical cancer screening in China II
Cervical cancer is a common malignant tumour that has become a major global public health issue, seriously threatening women’s lives. In November 2020, the WHO released a global strategy to accelerate the elimination of cervical cancer as a public health problem. So far, the proposal has received positive responses and commitments from 194 countries around the world, including China, which has actively promoted the prevention and treatment of cervical cancer nationwide. In support of the WHO initiative, in January 2023, the Chinese National Health Commission, along with other entities, issued a 7-year Action Plan for Accelerating the Elimination of Cervical Cancer (2023–2030), which primarily focused on improving the cervical cancer prevention and control service system and on strengthening its overall capacity. Furthermore, based on research evidence and practical experience, experts from seven Chinese academic societies—including the Chinese Society for Colposcopy and Cervical Pathology of China Healthy Birth Science Association and Chinese Society of Gynecological Oncology, Chinese Medical Association—have recently published the Guidelines for cervical cancer screening in China II (Guideline II). Unlike the previous Guidelines for cervical cancer screening in China I (Guideline I),1 which primarily focused on primary screening methods for cervical cancer, Guideline II emphasises the management and triage of abnormal primary screening results. As part of tertiary prevention, both screening and triage are critical steps in preventing the progression of cervical cancer, especially for those with abnormal test results. Here, we present a new guideline focused on standardising the triage of abnormal cervical cancer screening to improve management, reduce missed diagnoses and prevent overdiagnosis.
- Open Access
Lipid Nanoparticles Outperform Electroporation in Delivering Therapeutic HPV DNA Vaccines
Therapeutic HPV vaccines that induce potent HPV-specific cellular immunity and eliminate pre-existing infections remain elusive. Among various candidates under development, those based on DNA constructs are considered promising because of their safety profile, stability, and efficacy. However, the use of electroporation (EP) as a main delivery method for such vaccines is notorious for adverse effects like pain and potentially irreversible muscle damage. Moreover, the requirement for specialized equipment adds to the complexity and cost of clinical applications. As an alternative to EP, lipid nanoparticles (LNPs) that are already commercially available for delivering mRNA and siRNA vaccines are likely to be feasible. Here, we have compared three intramuscular delivery systems in a preclinical setting. In terms of HPV-specific cellular immune responses, mice receiving therapeutic HPV DNA vaccines encapsulated with LNP demonstrated superior outcomes when compared to EP administration, while the naked plasmid vaccine showed negligible responses, as expected. In addition, SM-102 LNP M exhibited the most promising results in delivering candidate DNA vaccines. Thus, LNP proves to be a feasible delivery method in vivo, offering improved immunogenicity over traditional approaches.
Open AccessLipid Nanoparticles Outperform Electroporation in Delivering Therapeutic HPV DNA Vaccines
Therapeutic HPV vaccines that induce potent HPV-specific cellular immunity and eliminate pre-existing infections remain elusive. Among various candidates under development, those based on DNA constructs are considered promising because of their safety profile, stability, and efficacy. However, the use of electroporation (EP) as a main delivery method for such vaccines is notorious for adverse effects like pain and potentially irreversible muscle damage. Moreover, the requirement for specialized equipment adds to the complexity and cost of clinical applications. As an alternative to EP, lipid nanoparticles (LNPs) that are already commercially available for delivering mRNA and siRNA vaccines are likely to be feasible. Here, we have compared three intramuscular delivery systems in a preclinical setting. In terms of HPV-specific cellular immune responses, mice receiving therapeutic HPV DNA vaccines encapsulated with LNP demonstrated superior outcomes when compared to EP administration, while the naked plasmid vaccine showed negligible responses, as expected. In addition, SM-102 LNP M exhibited the most promising results in delivering candidate DNA vaccines. Thus, LNP proves to be a feasible delivery method in vivo, offering improved immunogenicity over traditional approaches.
- Open Access
High-Risk Genotypes of Human Papillomavirus at Diverse Anogenital Sites among Chinese Women: Infection Features and Potential Correlation with Cervical Intraepithelial Neoplasia
Background: Both cervical cancer and cervical intraepithelial neoplasia (CIN) are associated with human papillomavirus (HPV) infection at different anogenital sites, but the infection features of high-risk (HR) HPVs at these sites and their association with cervical lesions have not been well characterized. Given the limitation of cervical HPV 16/18 test in screening patients with high-grade CIN (CIN 2+), studies on whether non-16/18 HR-HPV subtype(s) have potential as additional indicator(s) to improve CIN 2+ screening are needed. Methods: The infection of 15 HR-HPVs in vulva, anus, vagina, and cervix of 499 Chinese women was analyzed, and CIN lesion-associated HR-HPV subtypes were revealed. Results: In addition to the well-known cervical-cancer-associated HPV 16, 52, and 58, HPV 51, 53, and 56 were also identified as high-frequency detected subtypes prevalently and consistently present at the anogenital sites studied, preferentially in multi-infection patterns. HPV 16, 52, 58, 56, and 53 were the top five prevalent subtypes in patients with CIN 2+. In addition, we found that cervical HPV 33/35/52/53/56/58 co-testing with HPV 16/18 might improve CIN 2+ screening performance. Conclusion: This study provided a new insight into HR-HPV screening strategy based on different subtype combinations, which might be used in risk stratification clinically.
Open AccessHigh-Risk Genotypes of Human Papillomavirus at Diverse Anogenital Sites among Chinese Women: Infection Features and Potential Correlation with Cervical Intraepithelial Neoplasia
Background: Both cervical cancer and cervical intraepithelial neoplasia (CIN) are associated with human papillomavirus (HPV) infection at different anogenital sites, but the infection features of high-risk (HR) HPVs at these sites and their association with cervical lesions have not been well characterized. Given the limitation of cervical HPV 16/18 test in screening patients with high-grade CIN (CIN 2+), studies on whether non-16/18 HR-HPV subtype(s) have potential as additional indicator(s) to improve CIN 2+ screening are needed. Methods: The infection of 15 HR-HPVs in vulva, anus, vagina, and cervix of 499 Chinese women was analyzed, and CIN lesion-associated HR-HPV subtypes were revealed. Results: In addition to the well-known cervical-cancer-associated HPV 16, 52, and 58, HPV 51, 53, and 56 were also identified as high-frequency detected subtypes prevalently and consistently present at the anogenital sites studied, preferentially in multi-infection patterns. HPV 16, 52, 58, 56, and 53 were the top five prevalent subtypes in patients with CIN 2+. In addition, we found that cervical HPV 33/35/52/53/56/58 co-testing with HPV 16/18 might improve CIN 2+ screening performance. Conclusion: This study provided a new insight into HR-HPV screening strategy based on different subtype combinations, which might be used in risk stratification clinically.
- Open Access
PAX1/JAM3 Methylation and HPV Viral Load in Women with Persistent HPV Infection
The relationship of PAX1/JAM3 methylation as well as HPV viral load (VL) with cervical lesions has been reported, but their role in persistent HPV infection without cervical high-grade lesions has not been fully elucidated. A total of 231 females diagnosed with persistent HPV infection and pathologically confirmed absence of high-grade cervical lesions were selected from the Colposcopy Outpatient Clinic of Peking University People’s Hospital, from March 2023 to December 2023. They were categorized into two groups based on the duration of HPV infection: the HPV persistent less than 3 years group and the more than 3 years group. PAX1/JAM3 methylation and HPV VL were determined by real-time PCR and BioPerfectus Multiplex Real-Time (BMRT)-HPV reports type-specific VL/10,000 cells, respectively. The average age of individuals with HPV infection lasting more than 3 years was higher compared to those with less than 3 years (48.9 vs. 45.1 years), with a statistically significant difference. Among the participants, 81.8% (189/231) had no previous screening. The methylation levels of JAM3 and PAX1 were significantly higher in individuals with HPV infection persisting for more than 3 years compared to those with less than 3 years, with a statistically significant difference (p < 0.05). There was a significant correlation between PAX1 and JAM3 methylation (p < 0.001), which could be used as cumulative evidence of HPV infection duration before the occurrence of precancerous lesions. The incidence of vaginal intraepithelial lesions was higher in individuals with HPV infection persisting for more than 3 years compared to those with less than 3 years, and HPV VL can be used as an indicative biomarker for concurrent cervical–vaginal lesions, especially for HPV other than 16/18 genotypes.
Open AccessPAX1/JAM3 Methylation and HPV Viral Load in Women with Persistent HPV Infection
The relationship of PAX1/JAM3 methylation as well as HPV viral load (VL) with cervical lesions has been reported, but their role in persistent HPV infection without cervical high-grade lesions has not been fully elucidated. A total of 231 females diagnosed with persistent HPV infection and pathologically confirmed absence of high-grade cervical lesions were selected from the Colposcopy Outpatient Clinic of Peking University People’s Hospital, from March 2023 to December 2023. They were categorized into two groups based on the duration of HPV infection: the HPV persistent less than 3 years group and the more than 3 years group. PAX1/JAM3 methylation and HPV VL were determined by real-time PCR and BioPerfectus Multiplex Real-Time (BMRT)-HPV reports type-specific VL/10,000 cells, respectively. The average age of individuals with HPV infection lasting more than 3 years was higher compared to those with less than 3 years (48.9 vs. 45.1 years), with a statistically significant difference. Among the participants, 81.8% (189/231) had no previous screening. The methylation levels of JAM3 and PAX1 were significantly higher in individuals with HPV infection persisting for more than 3 years compared to those with less than 3 years, with a statistically significant difference (p < 0.05). There was a significant correlation between PAX1 and JAM3 methylation (p < 0.001), which could be used as cumulative evidence of HPV infection duration before the occurrence of precancerous lesions. The incidence of vaginal intraepithelial lesions was higher in individuals with HPV infection persisting for more than 3 years compared to those with less than 3 years, and HPV VL can be used as an indicative biomarker for concurrent cervical–vaginal lesions, especially for HPV other than 16/18 genotypes.
- Open Access
Association and Effectiveness of PAX1 Methylation and HPV Viral Load for the Detection of Cervical High-Grade Squamous Intraepithelial Lesion
Background: PAX1 methylation (PAX1m) and HPV viral load (VL) have been reported to detect cervical high-grade squamous intraepithelial lesions (HSIL), but the relationship between them is unclear. This study aimed to evaluate the correlation between HPV VL and PAX1m and its effectiveness in predicting cervical lesions. (2) Methods: A total of 476 women referred to colposcopy for abnormal cervical screening at the Peking University People’s Hospital between November 2020 and November 2021 were enrolled. PAX1m and HPV VL were determined by QMSP and BMRT-HPV reports type-specific VL/10,000 cells, respectively. (3) Results: PAX1m was significantly increased in HSIL, especially in cervical cancer, but there was no significant difference between cervical intraepithelial neoplasms 1(CIN1) and CIN2. However, HPV VL significantly differed between CIN1 and CIN2 but not between CIN3 and cervical cancer. In general, PAX1m positively correlated with all hrHPV VL, mainly in the HPV16/18 VL (p < 0.001), but had no relationship with the other 12 types of hrHPV VL. PAX1m had the highest specificity in diagnosing CIN2+, followed by HPV16/18 VL, which are higher than cytology ≥ASCUS. (4) Conclusions: Hypermethylation of PAX1 is associated with high HPV VL, especially HPV16/18, and both present advantageous specificity in detecting CIN2+.
Open AccessAssociation and Effectiveness of PAX1 Methylation and HPV Viral Load for the Detection of Cervical High-Grade Squamous Intraepithelial Lesion
Background: PAX1 methylation (PAX1m) and HPV viral load (VL) have been reported to detect cervical high-grade squamous intraepithelial lesions (HSIL), but the relationship between them is unclear. This study aimed to evaluate the correlation between HPV VL and PAX1m and its effectiveness in predicting cervical lesions. (2) Methods: A total of 476 women referred to colposcopy for abnormal cervical screening at the Peking University People’s Hospital between November 2020 and November 2021 were enrolled. PAX1m and HPV VL were determined by QMSP and BMRT-HPV reports type-specific VL/10,000 cells, respectively. (3) Results: PAX1m was significantly increased in HSIL, especially in cervical cancer, but there was no significant difference between cervical intraepithelial neoplasms 1(CIN1) and CIN2. However, HPV VL significantly differed between CIN1 and CIN2 but not between CIN3 and cervical cancer. In general, PAX1m positively correlated with all hrHPV VL, mainly in the HPV16/18 VL (p < 0.001), but had no relationship with the other 12 types of hrHPV VL. PAX1m had the highest specificity in diagnosing CIN2+, followed by HPV16/18 VL, which are higher than cytology ≥ASCUS. (4) Conclusions: Hypermethylation of PAX1 is associated with high HPV VL, especially HPV16/18, and both present advantageous specificity in detecting CIN2+.
- Open Access
- 27 July 2022
- Published by Wiley in Journal of Immunology Research
- Vol. 2022, 1-11
Age-Stratified Analysis of Vaginal Microbiota Dysbiosis and the Relationship with HPV Viral Load in HPV-Positive Women
Objective. This study evaluated the distribution of vaginal microbiota dysbiosis and the association with HPV viral load test in high-risk HPV-positive women before and after 50 years old. Methods. For this cross-sectional study, 388 HPV-positive women prior to referral to colposcopy in Peking University Peoples’ Hospital were included and classified as younger than 50 years ( ) and aged 50 years or older ( ), midvagina bacterial community composition was characterized by FlashDetect™ MAX vaginal microbe detection kit, and BMRT-HPV reported type-specific viral loads/10,000 cells. Results. The community state type (CST) IV was the most common CST occurring in 148 women (38.1%). The proportion of CST IV in those aged 50 years or older was significantly higher than those younger than 50 years (women) (66.7% vs. 30.6%); the difference was statistically significant ( and 0.263). However, the women with high-grade cervical lesion presented a more complicated trend and the abundance of vaginal microbiota dysbiosis than low-grade lesion. HPV16/18 viral load was found to be significantly higher in CST III and CST IV than CST I/II/V ( ) in women younger than 50 years. Conclusions. In women younger than 50 years, higher HPV16/18 load was more closely associated with CST IV; however, it had no significant correlation in women aged 50 years or older.
- 27 July 2022
- Published by Wiley in Journal of Immunology Research
- Vol. 2022, 1-11
Open AccessAge-Stratified Analysis of Vaginal Microbiota Dysbiosis and the Relationship with HPV Viral Load in HPV-Positive Women
Objective. This study evaluated the distribution of vaginal microbiota dysbiosis and the association with HPV viral load test in high-risk HPV-positive women before and after 50 years old. Methods. For this cross-sectional study, 388 HPV-positive women prior to referral to colposcopy in Peking University Peoples’ Hospital were included and classified as younger than 50 years ( ) and aged 50 years or older ( ), midvagina bacterial community composition was characterized by FlashDetect™ MAX vaginal microbe detection kit, and BMRT-HPV reported type-specific viral loads/10,000 cells. Results. The community state type (CST) IV was the most common CST occurring in 148 women (38.1%). The proportion of CST IV in those aged 50 years or older was significantly higher than those younger than 50 years (women) (66.7% vs. 30.6%); the difference was statistically significant ( and 0.263). However, the women with high-grade cervical lesion presented a more complicated trend and the abundance of vaginal microbiota dysbiosis than low-grade lesion. HPV16/18 viral load was found to be significantly higher in CST III and CST IV than CST I/II/V ( ) in women younger than 50 years. Conclusions. In women younger than 50 years, higher HPV16/18 load was more closely associated with CST IV; however, it had no significant correlation in women aged 50 years or older.